ERT

Charles Bodner Joins CSafe Global as Chief Financial Officer

Wednesday, September 15, 2021 - 5:17pm

DAYTON, Ohio, Sept. 15, 2021 /PRNewswire/ -- CSafe Global, the innovation leader in temperature-controlled solutions for the pharmaceutical industry, announced today that Charles ('Chuck') Bodner has joined the company's executive team as Chief Financial Officer. 

Key Points: 
  • CSafe Global has hired Charles Bodner as CFO following Patrick Schafer's promotion to CEO in 2020.
  • DAYTON, Ohio, Sept. 15, 2021 /PRNewswire/ -- CSafe Global , the innovation leader in temperature-controlled solutions for the pharmaceutical industry, announced today that Charles ('Chuck') Bodner has joined the company's executive team as Chief Financial Officer.
  • Prior to joining CSafe Global, he held senior level positions with Sanofi-Aventis, Schering-Plough, AstraZeneca, Becton Dickinson and Bioclinica.
  • "After helping Bioclinica successfully complete its merger with ERT, I am very excited to be joining the CSafe team," Bodner said.

Charles Bodner Joins CSafe Global as Chief Financial Officer

Wednesday, September 15, 2021 - 4:42pm

DAYTON, Ohio, Sept. 15, 2021 /PRNewswire/ -- CSafe Global, the innovation leader in temperature-controlled solutions for the pharmaceutical industry, announced today that Charles ('Chuck') Bodner has joined the company's executive team as Chief Financial Officer. 

Key Points: 
  • CSafe Global has hired Charles Bodner as CFO following Patrick Schafer's promotion to CEO in 2020.
  • DAYTON, Ohio, Sept. 15, 2021 /PRNewswire/ -- CSafe Global , the innovation leader in temperature-controlled solutions for the pharmaceutical industry, announced today that Charles ('Chuck') Bodner has joined the company's executive team as Chief Financial Officer.
  • Prior to joining CSafe Global, he held senior level positions with Sanofi-Aventis, Schering-Plough, AstraZeneca, Becton Dickinson and Bioclinica.
  • "After helping Bioclinica successfully complete its merger with ERT, I am very excited to be joining the CSafe team," Bodner said.

Freeline Announces Orphan Drug Designations for FLT201 for the Treatment of Gaucher Disease

Thursday, September 9, 2021 - 12:00pm

Receiving orphan drug designation for FLT201 is an important regulatory milestone in delivering on the promise of our Gaucher program to address the urgent, unmet need of patients living with Gaucher disease Type 1.

Key Points: 
  • Receiving orphan drug designation for FLT201 is an important regulatory milestone in delivering on the promise of our Gaucher program to address the urgent, unmet need of patients living with Gaucher disease Type 1.
  • The Company remains on track to initiate our Phase 1/2 dose-finding trial in Gaucher disease Type 1 before year end, continued Mr. Parini.
  • FLT201 is an investigational liver-directed AAV gene therapy in preclinical development for the treatment of Gaucher disease Type 1.
  • The Company has clinical programs in HemophiliaB and Fabry disease, as well as preclinical programs in Gaucher disease Type 1 and HemophiliaA.

How to Reinvent and Scale Decentralized Clinical Trials, Upcoming Webinar Hosted by Xtalks

Thursday, September 2, 2021 - 1:30pm

TORONTO, Sept. 2, 2021 /PRNewswire-PRWeb/ -- The adoption of decentralized clinical trials (DCTs) has increased over the past 18 months due to the COVID-19 pandemic.

Key Points: 
  • TORONTO, Sept. 2, 2021 /PRNewswire-PRWeb/ -- The adoption of decentralized clinical trials (DCTs) has increased over the past 18 months due to the COVID-19 pandemic.
  • The digitization of clinical trials has revealed numerous benefits to both study sponsors and patients, including streamlining of clinical operations, reducing patient and investigator burden, accelerating clinical trial timelines, and increasing patient diversity, compliance and retention.
  • With the advantages of DCTs so apparent, studies are left looking for new ways to capture medical-grade data remotely and securely.
  • For more information, or to register for this event, visit How to Reinvent and Scale Decentralized Clinical Trials.

SureCall Introduces Fusion4Home Max, Strongest Residential Cell Booster For Maximum Coverage and Connectivity

Wednesday, September 1, 2021 - 1:00pm

FREMONT, Calif., Sept. 1, 2021 /PRNewswire/ --SureCall, the technology and performance leader among cell phone signal booster manufacturers, today introduced the Fusion4Home Max, its strongest all-carrier residential booster that is purpose-built for areas with the weakest cellular signals.

Key Points: 
  • FREMONT, Calif., Sept. 1, 2021 /PRNewswire/ --SureCall, the technology and performance leader among cell phone signal booster manufacturers, today introduced the Fusion4Home Max, its strongest all-carrier residential booster that is purpose-built for areas with the weakest cellular signals.
  • As the first home cellular booster to feature SureCall's patented Extended Range Technology (ERT), which overcomes the signal loss in the outdoor cable, the Fusion4Home Max amplifies cell signals at the strongest point outside the building before sending inside.
  • This enables the Fusion4Home Max to provide maximum coverage and connectivity for multiple simultaneous users on all 4G LTE and 5G cellular devices, including hotspots.
  • The cutting-edge technology of the Fusion4Home Max transforms customers' current connectivity more than any other home cellular signal booster."

Lowe's Pledges $2 Million In Wake Of Hurricane Ida To Support Relief Efforts

Monday, August 30, 2021 - 5:00pm

MOORESVILLE, N.C., Aug. 30, 2021 /PRNewswire/ --Lowe's today announced it will donate $2 million to support relief efforts after Hurricane Ida devastated the Gulf Coast, causing catastrophic flooding and damage.

Key Points: 
  • MOORESVILLE, N.C., Aug. 30, 2021 /PRNewswire/ --Lowe's today announced it will donate $2 million to support relief efforts after Hurricane Ida devastated the Gulf Coast, causing catastrophic flooding and damage.
  • As part of today's announcement,Lowe'swill donate$1 million to disaster relief partners including the American Red Cross, St. Bernard Project and others, helping organizations to provide emergency shelter, food, relief and rebuilding supplies and comfort to those affected by Hurricane Ida.
  • "Our thoughts and prayers are with the communities devastated by Hurricane Ida," said Marvin R. Ellison, Lowe's chairman and CEO.
  • They will provide additional customer support and give fellow associates impacted by the hurricane a chance to focus on their families.

Mindset raises over $20,000 US to help India

Tuesday, August 17, 2021 - 1:30pm

With two locations and a global team we care about in India, Mindset has been committed to helping address this crisis.

Key Points: 
  • With two locations and a global team we care about in India, Mindset has been committed to helping address this crisis.
  • "We are so excited by the results of our efforts and happy we could do something to help," said Mindset CEO, Gavin Quinn.
  • "We are pleased and grateful for the response to our fundraising efforts," added Parvathy Sankar, Managing Director of Mindset India and VP at Mindset.
  • Announced in January 2021, Mindset India currently has two locations and over 30 employees located in facilities in Mindset Bengaluru and Mindset Hyderabad .

Muscular Dystrophy Association Celebrates FDA Approval of (Nexviazyme) for Treatment of Pompe disease

Friday, August 6, 2021 - 9:21pm

NEW YORK, Aug. 6, 2021 /PRNewswire/ --The Muscular Dystrophy Association (MDA) today celebrates the decision by the US Food and Drug Administration (FDA) to grant accelerated marketing approval to avalglucosidase alfa(Nexviazyme) for the treatment of people 1 year of age and older living with late-onset Pompe disease.

Key Points: 
  • NEW YORK, Aug. 6, 2021 /PRNewswire/ --The Muscular Dystrophy Association (MDA) today celebrates the decision by the US Food and Drug Administration (FDA) to grant accelerated marketing approval to avalglucosidase alfa(Nexviazyme) for the treatment of people 1 year of age and older living with late-onset Pompe disease.
  • "The approval of Nexviazyme provides another option for patients with Pompe disease," says MDA's Executive Vice President and Chief Research Officer Sharon Hesterlee, PhD.
  • Pompe disease is a rare degenerative muscle disorder that affects approximately 3,500 people in the US.
  • For 70 years, the Muscular Dystrophy Association (MDA) has been committed to transforming the lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases.

FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease

Friday, August 6, 2021 - 4:42pm

Nexviazyme is a potential new standard of care for people living with late-onset Pompe disease and delivers on our promise to pursue medicines for patients living with rare diseases.

Key Points: 
  • Nexviazyme is a potential new standard of care for people living with late-onset Pompe disease and delivers on our promise to pursue medicines for patients living with rare diseases.
  • Pompe disease affects an estimated 3,500 people in the United States and can present as infantile-onset Pompe disease (IOPD), the most severe form of Pompe disease with rapid onset in infancy, and late-onset Pompe disease (LOPD), which progressively damages muscles over time.
  • 3) provides personalized support for people and their families impacted by Pompe disease, including patients transitioning to Nexviazyme.
  • Previously, Nexviazyme received FDA Breakthrough Therapy and Fast Track designations for the treatment of people with Pompe Disease.

Clarivate Acquires Bioinfogate, Reinforcing Position as Premier Provider of End-to-End Research Intelligence Solutions for Life Sciences

Wednesday, August 4, 2021 - 9:00am

LONDON, Aug. 4, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that it has acquired Bioinfogate, a leading provider of analytics solutions in the life sciences and producer of the OFF-X™ portal. Financial terms of the transaction were not disclosed.   

Key Points: 
  • As a leading provider of trusted information and insights to accelerate innovation, Clarivate offerings include a comprehensive suite of research intelligence solutions coupled with deep domain expertise.
  • The acquisition ofBioinfogatewill fill a critical need for drug toxicity data and translational safety intelligence across all stages of drug R&D.
  • In addition, through a 2019 partnership withBioinfogate, Clarivate integrated OFF-X translational safety intelligence data withCortellis products, includingCortellisDrug Discovery andCortellisCompetitive Intelligence.
  • Mukhtar Ahmed, President, Science Group, Clarivate:"The acquisition ofBioinfogatewill further our strategy to become an essential provider of solutions for life science companies along the entire drug development lifecycle.